Improved diagnosis of the transition to JAK2V617F homozygosity: The key feature for predicting the evolution of myeloproliferative neoplasms

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Gonzalez, Mariana Selena ^a   De Brasi, Carlos Daniel ^a,b   Bianchini, Michele ^c   Gargallo, Patricia ^b   Stanganelli, Carmen ^b   Zalcberg, Ilana ^d   Larripa, Irene Beatriz ^a,b  

^a ACADEMIA NACIONAL DE MEDICINA   (Argentina)

^b INST DE INVEST HEMATOLOGICAS   (Argentina)

^c INSTITUTO ALEXANDER FLEMING   (Argentina)

^d INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; GENOMIC DNA; JANUS KINASE 2;

ADULT; AGED; ALLELE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE AMPLIFICATION; GENE FUSION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; JAK2 GENE; MALE; MYELOPROLIFERATIVE NEOPLASM; PREDICTION; REAL TIME POLYMERASE CHAIN REACTION;

DNA PRIMERS; GENE FREQUENCY; HUMANS; JANUS KINASE 2; LEUKEMIA, MYELOID, CHRONIC, ATYPICAL, BCR-ABL NEGATIVE; LOSS OF HETEROZYGOSITY; MUTATION, MISSENSE; MYELOPROLIFERATIVE DISORDERS; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84899913333     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0086401     Document Type: Article

References (24)

1. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, et al. (2005) Acquired mutations of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365: 1054-1061. (Pubitemid 40386783)
2. James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, et al. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434: 1144-1148. (Pubitemid 40663494)
3. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, et al. (2005) A gain of function mutation of JAK2 in Myeloproliferative Disorders. N Engl J Med 352: 1779-1790. (Pubitemid 40570926)
4. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, et al. (2005) Acting mutation in the tyrosine kinase JAK2 in polycithemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis. Cancer Cell 7: 387-397. (Pubitemid 40544655)
5. Zhao R, Xing S, Li Z, Fu X, Li Q, et al. (2005) Identification of an acquired JAK2 mutation in polycythemia vera. J. Biol. Chem 280: 22788-22792. (Pubitemid 40853184)
6. Parganas E, Wang D, Stravopodis D, Topham DJ, Marine JC, et al. (1998) JAK2 is essential for signaling through a variety of cytokine receptors. Cell 93: 385-395. (Pubitemid 28232083)
7. Vainchenker W, Constantinescu S (2005) A unique activating mutation in JAK2 (V617) is at the Origin of polycythemia vera and allows a new classification of myeloproliferative diseases. Hematology Am Soc Hematol Educ Program 195-200.
8. Levine RL, Pardanani A, Tefferi A, Gilliland DG (2007) Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 7: 673-683. (Pubitemid 47327415)
9. Vannucchi AM, Antonioli E, Guglielmelli P, Longo G, Pancrazzi A, et al. (2007) MPD Research Consortium: Prospective identification of high-risk polycythemia vera patients based on JAK2 V617F allele burden. Leukemia 21: 1952-1959. (Pubitemid 47299969)
10. Carobbio A, Finazzi G, Antonioli E, Guglielmelli P, Vannucchi AM, et al. (2009) JAK2V617F allele burden and thrombosis: A direct comparison in essential thrombocythemia and polycythemia vera. Exp Hematol 37: 1016-1021.
11. Passamonti F, Rumi E (2009) Clinical relevance of JAK2 (V617F) mutant allele burden. Haematologica 94: 7-10.
12. Chen G, Prchal J (2006) Polycythemia vera and its molecular basis: An update. Best Pract Res Clin Haematol. 19: 387-397. (Pubitemid 43884242)
13. Vannucchi A, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A (2008) Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia 22: 1299-1307.
14. Vannucchi AM, Pancrazzi A, Bogani C, Antonioli E, Guglielmelli P (2006) A quantitative assay for JAK2 V617F mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis. Leukemia 20: 1055-1060. (Pubitemid 43797297)
15. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, et al. (2005) Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106: 2162-2168. (Pubitemid 41291734)
16. Bousquet M, Le Guellec S, Quelen C, Rigal-Huguet F, Delsol G, et al. (2006) Frequent detection of the JAK2 V617F mutation in bone marrow core biopsy specimens from chronic myeloproliferative disorders using the TaqMan polymerase chain reaction single nucleotide polymorphism genotyping assay. A retrospective study with pathologic correlations. Hum Pathol 37: 1458-1464. (Pubitemid 44584325)
17. Tefferi A, Terra M, Lasho L, Gilliland G (2005) JAK2 Mutations in Myeloproliferative Disorders. N Engl J Med 353: 1416-1417.
18. Campbell PJ, Green AR (2006) The Myeloproliferative Disorders. N Engl J Med 355: 2452-2466. (Pubitemid 44903749)
19. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, et al. (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114: 937-951.
20. Lippert E, Girodon F, Hammond E, Jelinek J, Reading NS, et al. (2009) Concordance of assays designed for the quantification of JAK2V617F: a multicenter study. Haematologica 94: 38-45.
21. Jovanovic J, Ivey A, Vannuchi A, Lippert E, Oppliger Leibundgut E, et al. (2013) Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study. Leukemia 27: 2032-2039.
22. Quentmeier H, MacLeod R, Zaborski M, Drexler H (2006) JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia 20: 471-476. (Pubitemid 43291746)
23. Lippert E, Boissinot M, Kralovics R, Girodon F, Dobo I, et al. (2006) The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood 108: 1865-1867. (Pubitemid 44394995)
24. Tiedt R, Hao-Shen H, Sobas MA, Looser R, Dirnhofer S, et al. (2008) Ratio of mutant JAK2V617F to wild type Jak2 determines the MPD phenotypes in transgenic mice. Blood 111: 3931-3940.